As the Senior Director of Biopharma Business Development at Zephyr AI, Bill Keating leverages his extensive experience in biotechnology to forge strategic partnerships that drive innovation and enhance patient outcomes. With a focus on delivering interpretable AI and machine learning-powered insights, Bill plays a pivotal...
As the Senior Director of Biopharma Business Development at Zephyr AI, Bill Keating leverages his extensive experience in biotechnology to forge strategic partnerships that drive innovation and enhance patient outcomes. With a focus on delivering interpretable AI and machine learning-powered insights, Bill plays a pivotal role in transforming the landscape of drug development. His expertise encompasses the entire spectrum of biopharma—from target discovery to label optimization—enabling clients to navigate the complexities of regulatory frameworks and expedite the approval of novel oncology therapies.
Under Bill's leadership, Zephyr AI has embarked on several key projects that harness real-world data to validate AI-driven insights, ensuring that biopharma clients can make informed decisions throughout the commercialization process. His strategic vision has facilitated collaborations with diagnostics and life science tools companies, positioning Zephyr AI as a leader in the integration of cutting-edge technology into the biopharma sector. Bill's adeptness at negotiating corporate partnerships and executing high-stakes transactions has not only enhanced the company’s portfolio but has also contributed to significant advancements in molecular diagnostics and medical devices.
With a background in R&D and a keen understanding of marketing strategy within the pharmaceutical industry, Bill is uniquely equipped to bridge the gap between scientific innovation and market needs. His commitment to improving drug development outcomes is further evidenced by his hands-on experience in product development and acquisitions, making him a valuable asset to both Zephyr AI and the broader biopharma community.
